ABG
OLMA icon

Ally Bridge Group’s Olema Pharmaceuticals OLMA Stock Holding History

Ally Bridge Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-559,035
Closed -$6.33M – 29
2024
Q1 		$6.33M Sell
559,035
-100,000
-15% -$1.29M 3.52% 15
2023
Q4 		$9.25M Buy
+659,035
New +$8.86M 5.51% 7

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ally Bridge Group's OLMA Position: Q2 2024 in Review

Ally Bridge Group sold out of Olema Pharmaceuticals (OLMA) in Q2 2024, closing a stake of 559,035 shares — an estimated $6.33M sold.

Ally Bridge Group first reported a position in OLMA in Q4 2023 and held it in 2 quarters. The position peaked at $9.25M in Q4 2023. 128 funds tracked by Wall St. Rank hold OLMA as of Q2 2024.

  • Ally Bridge Group reported no remaining Olema Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Ally Bridge Group sold 559,035 Olema Pharmaceuticals shares in Q2 2024, an estimated $6.33M.
  • Ally Bridge Group first reported a position in Olema Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Ally Bridge Group's Olema Pharmaceuticals position peaked at $9.25M in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2024.

Based on Ally Bridge Group's 13F filing for Q2 2024, filed 14 Aug 2024.